Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.112
Peer-review started: September 23, 2022
First decision: November 16, 2022
Revised: November 23, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 15, 2023
Processing time: 109 Days and 5.4 Hours
The prediction and early detection of metachronous peritoneal metastasis (m-PM) remain a difficult task in clinical practice. Few studies have reported the genetic alterations of m-PM.
To explore risk factors in patients with m-PM after curative-intent colorectal cancer (CRC) surgery.
To establish and validate a nomogram model for predicting the occurrence of m-PM in CRC within 3 years after surgery.
We used the clinical data of 878 patients at the Second Hospital of Jilin University, between January 1, 2014 and January 31, 2019. The patients were randomly divided into training and validation cohorts at a ratio of 2:1. All data were analyzed using SPSS version 26.0 and R version 4.0.3.
The 3-year cumulative incidence of m-PM was 11.1% (65/586) in the training cohort and 9.9% (29/292) in the validation cohort. Least absolute shrinkage and selection operator regression analysis and multiple logistic regressions identified that right colon cancer, pT4, histological types of mucinous adenocarcinoma and signet-ring cell carcinoma, elevated carbohydrate antigen 125 (CA125), v-raf murine sarcoma viral oncogene homolog B (BRAF) mutation, and microsatellite instability-high-frequency (MSI-H) were independent risk factors for m-PM in CRC. These six predictors could be used to establish a nomogram for predicting m-PM. The nomogram model showed good discrimination accuracy, calibration, and reliability in both training and validation cohorts.
The nomogram model based on six predictors (right colon cancer, pT4, and histological types of mucinous adenocarcinoma and signet-ring cell carcinoma, elevated CA125, BRAF mutation, and MSI-H) showed good discrimination and high accuracy.
The nomogram requires further validation in multicenter prospective clinical studies.
